CAJ | 학술논문

目的：观察利拉鲁肽对初诊肥胖2型糖尿病患者的疗效及安全性。方法初诊肥胖的2型糖尿病患者经口服二甲双胍治疗后血糖仍未达标者40例，在继续口服二甲双胍的基础上联合利拉鲁肽治疗12周，观察治疗前后空腹血糖(FPG)、空腹C肽(FC-P)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、腰围及体质量指数(BMI)的变化，记录不良反应。结果治疗后患者的FPG、2 h PG、HbA1c、腰围、BMI均较治疗前降低，差异有统计学意义(P<0.05)；FC-P升高，差异有统计学意义(P<0.05)；部分患者有恶心、腹泻等症状，但均可耐受，无低血糖发生。结论对于初诊肥胖的2型糖尿病患者，在口服二甲双胍后血糖未达标，加用利拉鲁肽治疗可有效降低患者的血糖，减轻体重，改善胰岛功能。
목적：관찰리랍로태대초진비반2형당뇨병환자적료효급안전성。방법초진비반적2형당뇨병환자경구복이갑쌍고치료후혈당잉미체표자40례，재계속구복이갑쌍고적기출상연합리랍로태치료12주，관찰치료전후공복혈당(FPG)、공복C태(FC-P)、찬후2 h혈당(2 h PG)、당화혈홍단백(HbA1c)、요위급체질량지수(BMI)적변화，기록불량반응。결과치료후환자적FPG、2 h PG、HbA1c、요위、BMI균교치료전강저，차이유통계학의의(P<0.05)；FC-P승고，차이유통계학의의(P<0.05)；부분환자유악심、복사등증상，단균가내수，무저혈당발생。결론대우초진비반적2형당뇨병환자，재구복이갑쌍고후혈당미체표，가용리랍로태치료가유효강저환자적혈당，감경체중，개선이도공능。
Objective To observe the curative effect and safety of liraglutide in the treatment of newly diagnosed obesity type 2 diabetes mellitus. Methods A total of 40 patients with newly diagnosed obesity type 2 diabetes mellitus were selected as study subject, who had abnormal blood glucose after oral administration of melbine. They received additional liraglutide treatment for 12 weeks. The changes of fasting plasma glucose (FPG), fasting C-peptide (FC-P), 2 h plasma glucose (2 h PG), glycosylated hemoglobin (HbA1c), waistline, and body mass index (BMI) were all compared before and after treatment. Adverse reactions were recorded. Results After the treatment, the levels of FPG, 2 h PG, HbA1c, waistline and BMI were significantly decreased, and the difference had statistical significance (P<0.05). The level of FC-P was increased, and the difference had statistical significance (P<0.05). Some of the patients had tolerable symptoms of nausea and diarrhea, and had no hypoglycemia. Conclusion The additional liraglutide to melbine oral treatment can effectively control blood glucose, reduce weight, and improve pancreas islet function in patients with newly diagnosed obesity type 2 diabetes mellitus, who have blood glucose blow the standard.